Continuum Health

Longevity therapeutics · biomarker diagnostics

Aging is a variable. We're learning to set it.

Continuum builds therapeutics that clear the cellular debris of aging, and a biomarker panel precise enough to measure whether they work. Not a wellness score — a clinical readout of how fast your body is aging, and a program to bend the curve.

Request early-access screening How we measure aging →
Biological age · cohort median 0yrs
−7.4 yrs vs chronological age, modelled from a 214-marker panel across 12 clinic visits.

[ The thesis ]

We treat aging as measurable, and therefore modifiable.

Hallmarks of aging — senescent-cell burden, epigenetic drift, mitochondrial decline — are quantifiable. Continuum measures them, targets them, and re-measures. The loop is the product.

01

Measure the clock, not the calendar

A DNA-methylation clock and a 214-marker blood panel estimate biological age directly, so a therapy is judged by whether the clock slows — not by how a patient feels that week.

02

Clear the cells that stopped dividing

Senescent cells accumulate and leak inflammatory signals into healthy tissue. Our lead candidates drive targeted apoptosis of p16-positive cells while sparing the rest.

03

Close the loop every quarter

Each participant re-panels on a fixed cadence. Dose, biomarker response, and epigenetic-age trajectory feed one longitudinal record — the same record that steers the next protocol revision.

[ Therapeutic pipeline ]

Five programs, one endpoint: slower biological aging.

Each program targets a distinct hallmark. Position on the rail shows the furthest phase reached in our internal model.

Positions are illustrative of a design concept. Continuum runs no clinical trials.

[ Biomarker dashboard ]

The readout every participant sees.

Ten markers roll up to one biological-age estimate. Each is graded against its optimal band — green is where we want you, not simply "normal for your age."

Senescence load · p16INK4a relative units · 12 clinic visits · CN-01 cohort
41−47%
0Participants enrolled
0Biomarkers per panel
0yrsHealthspan extended · in model
0Clinical sites

[ Early access ]

Get your baseline. Then watch it change.

Screening starts with the full 214-marker panel and your first biological-age estimate. If you match an active program, a clinician walks you through the protocol before anything begins.

IRB-style review, clinician oversight, and consent precede any dosing. This is a design concept — no data is collected and no screening is scheduled.